drugset / Trial / NCT04994561
VIAging Deceleration Trial Using Metformin, Dasatinib, Rapamycin and Nutritional Supplements
NaSingle-groupOpen-labelTreatment
Summary
This study aims to assess the safety and efficacy of study drugs and supplements on clinical (structural and functional) signs of aging and to explore/identify other possible biological measures of aging.
Timeline
- Start
- 2022-06
- Primary completion
- 2023-12
- Completion
- 2023-12
Outcome
Outcome not reported
Stopped: “Study was withdrawn”
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | Glucosamine | Small molecule | 1500 mg | — |
| Subject | Metformin | Small molecule | 2000 mg | — |
| Subject | Nicotinamide riboside | Small molecule | 600 mg | — |
| Subject | Rapamycin | Small molecule | 6 mg | — |
| Subject | Resveratrol | Small molecule | 500 mg | — |
| Subject | bio-fisetin | Unknown | 44.5 mg | — |
| Subject | bio-quercetin | Unknown | 58 mg | — |
| Subject | bio-quercetin | Unknown | 174 mg | — |
| Subject | dasatinib anhydrous | Small molecule | 140 mg | — |
Indications
No indication recorded.